RU
Rubicon Research Ltd (RUBICON)
₹1,520.20
Mkt cap
₹25,141 Cr
P/E ratio
102.00
P/B
19.46
Div yield
0.10%
ROE
27.00%
ROCE
28.40%
EPS (TTM)
₹14.90
Book value
₹78
52W range
577–1,525
Sector
Healthcare
Incorporated in 1999, Rubicon Research Limited is a pharmaceutical company engaged in the development, manufacturing, & commercialization of differentiated formulations. [1]
Health check
Constructive
ValuationExpensive
ProfitabilityStrong
GrowthHigh
TechnicalsNeutral
52-week range
−0.34% from high₹1,520
₹577+163.35% from low₹1,525
Current
₹1,520.20
Prev close
₹1,522.00
Day
−0.12%
Price performance
1D
−0.12%
1W
+0.56%
1M
+7.31%
3M
+61.95%
6M
+129.00%
1Y
—
YTD
+129.85%
Financials
FRevenue, profit & margin
P/E ratio
102.0×
RUBICON is 200% above the sector median of 34.0×
RUBICON102.0×
Sector median34.0×
| Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|
| Sales | 296 | 313 | 358 | 352 | 412 | 476 | 514 | |
| Expenses | 234 | 244 | 286 | 273 | 318 | 367 | 395 | |
| Operating Profit | 62 | 70 | 72 | 79 | 94 | 108 | 119 | |
| OPM % | 21% | 22% | 20% | 22% | 23% | 23% | 23% | |
| Other Income | 3 | 0 | 0 | 1 | 1 | 4 | 3 | |
| Interest | 7 | 8 | 12 | 11 | 11 | 10 | 10 | |
| Depreciation | 8 | 9 | 10 | 10 | 12 | 12 | 12 | |
| Profit before tax | 49 | 53 | 51 | 60 | 72 | 91 | 99 | |
| Tax % | 30% | 28% | 29% | 27% | 25% | 20% | 22% | |
| Net Profit | 34 | 38 | 36 | 43 | 54 | 73 | 77 | |
| EPS in Rs | 2.27 | 2.50 | 2.35 | 2.81 | 3.49 | 4.42 | 4.65 | |
| Raw PDF |
Earnings
EResults dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Corporate actions
CLast 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Shareholding
Sas of Jun 202659.76%Promoter
Promoters59.76%0.10
FIIs7.52%0.02
DIIs9.43%0.59
Public23.29%0.72
Ownership trend
Peers
P8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma.Inds. | ₹1,941.10 | 37.48 | 4,65,735 | 0.82% | 2,710 | +13.58% | 14,612 | +12.76% | 20.53% |
| Divi's Lab. | ₹7,248.50 | 73.36 | 1,92,425 | 0.41% | 751 | +13.44% | 2,831 | +9.52% | 21.97% |
| Torrent Pharma. | ₹4,961.50 | 86.11 | 1,88,720 | 0.77% | 364 | −20.58% | 4,197 | +41.84% | 15.19% |
| Cipla | ₹1,410.60 | 31.84 | 1,13,955 | 0.92% | 786 | −39.19% | 7,119 | +2.33% | 15.49% |
| Zydus Lifesci. | ₹1,108.70 | 20.38 | 1,10,593 | 0.09% | 1,341 | +21.92% | 7,587 | +16.22% | 21.14% |
| Lupin | ₹2,370.50 | 19.06 | 1,08,387 | 0.76% | 1,469 | +101.49% | 7,475 | +31.89% | 29.93% |
| Mankind Pharma | ₹2,507.20 | 51.44 | 1,03,546 | 0.04% | 559 | +34.23% | 3,443 | +11.81% | 13.53% |
| Rubicon Research | ₹1,520.20 | 101.89 | 25,141 | 0.10% | 77 | +111.83% | 514 | +43.49% | 28.35% |
| Median: 157 Co. | ₹432.05 | 34.03 | 1,978 | 0.10% | 15 | +28.10% | 176 | +17.66% | 15.10% |
Filings
DAnnual reports1
Concall transcripts8
Credit ratings2
Announcements5
Filing Of Scheme Of Merger Of Kia Health Tech Private Limited (Wholly Owned Subsidiary) With Rubicon Research Limited - For Disclosure Purposes Only, In Terms Of The Exemption Under Paragraph 4 Of SEBI Master Circular No. SEBI/HO/CFD/POD-2/P/CIR/2023/93 Dated June 20, 2023 2d - Board approved merger of Kia Health Tech into Rubicon, appointed date April 1, 2026, pending approvals.Announcement under Regulation 30 (LODR)-Press Release / Media Release 2d - Rubicon acquired first US manufacturing facility in New Jersey for USD 2.9 million on 21 July 2026.Record Date For Payment Of Final Dividend - Friday, August 7, 2026 20 JulOutcome Of Board Meeting 20 Jul - AGM on Aug 26, 2026; record date Aug 7; ₹1.50 final dividend and Kia Health Tech merger approved.Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS 20 Jul